C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/00 (2006.01) A61K 31/7088 (2006.01) A61K 31/7105 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) A61K 48/00 (2006.01) A61P 29/00 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2501422
Experimental autoimmune encephalomyelitis (EAE) is a Th1-mediated autoimmune disease of the central nervous system that is widely used as an animal model of multiple sclerosis (MS). In this study it was demonstrate that CXCL13, a chemokine involved in the development of secondary lymphoid tissues, is expressed in CD11c+ myeloid cells that accumulate in EAE lesions. Blockade or deficiency of CXCL13 ameliorates clinical EAE, both during acute and relapsing stages. CXCL13 deficiency did not inhibit the priming or differentiation of autoimmune effector T cells in the periphery, but appeared to exert its effects during the effector phase of pathogenesis. These findings indicate that reagents that antagonize or inhibit CXCL13 are useful for the treatment of neuroinflammatory diseases such as MS.
Bagaeva Ludmila
Segal Benjamin M.
Mbm Intellectual Property Law Llp
University Of Rochester
LandOfFree
Lymphoid chemokines in the diagnosis, monitoring and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphoid chemokines in the diagnosis, monitoring and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphoid chemokines in the diagnosis, monitoring and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1714512